Race Oncology Limited (ASX: RAC) (Race) is pleased to release an updatedinvestor presentation and invite investors to join a special online investor briefing. Updated Presentation An update on the Company's…

In >40 clinical trials, Bisantrene has been shown to have low cardiotoxicityThis study will assess the molecular mechanisms of Bisantrene heart safety usingcurrent molecular biology techniquesLed by an established chemotherapeutic…

Former Senior Vice President of Clinical Development at Syneos HealthDr Fuller brings over 30 years’ experience in oncology, international markets, listedbusinesses and is a highly experienced pharmaceutical physicianAppointment follows an…

Professor Jianjun Chen of the City of Hope Hospital appointed to Race’s Scientific Advisory BoardProf Chen is one of the foremost leaders in the m6A RNA methylation field and discovered…

Bisantrene shown by the University of Chicago to target the Fat Mass and Obesity associated protein (FTO)Bisantrene able to treat skin cancer in mice via inhibition of FTO at non-toxic…